Alaunos Therapeutics (NASDAQ:TCRT) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Alaunos Therapeutics (NASDAQ:TCRTGet Rating) from a hold rating to a buy rating in a research report released on Wednesday morning, Zacks.com reports. The brokerage currently has $0.50 price objective on the stock.

According to Zacks, “Alaunos Therapeutics Inc. is a clinical-stage oncology-focused cell therapy company. It focused on developing T-cell receptor therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform. Alaunos Therapeutics Inc., formerly known as Ziopharm Oncology Inc., is based in HOUSTON. “

Other equities analysts also recently issued research reports about the stock. Raymond James set a $2.00 price target on shares of Alaunos Therapeutics and gave the stock a market perform rating in a research note on Friday, April 1st. HC Wainwright reaffirmed a neutral rating on shares of Alaunos Therapeutics in a research note on Thursday, March 31st. Wells Fargo & Company raised shares of Alaunos Therapeutics from an equal weight rating to an overweight rating and set a $3.00 price target on the stock in a research note on Wednesday. Finally, Cantor Fitzgerald reaffirmed an overweight rating on shares of Alaunos Therapeutics in a research note on Friday, April 1st. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Buy and an average target price of $1.83.

Shares of TCRT opened at $0.75 on Wednesday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 4.91 and a current ratio of 4.91. Alaunos Therapeutics has a 1 year low of $0.41 and a 1 year high of $3.73.

Alaunos Therapeutics (NASDAQ:TCRTGet Rating) last announced its quarterly earnings data on Wednesday, March 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.03. On average, equities research analysts forecast that Alaunos Therapeutics will post -0.32 earnings per share for the current fiscal year.

About Alaunos Therapeutics (Get Rating)

Alaunos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells.

Further Reading

Get a free copy of the Zacks research report on Alaunos Therapeutics (TCRT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.